Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $5.43 Consensus PT from Analysts
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been given a consensus rating of “Hold” by the nine research firms that are presently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average […]
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been given a consensus rating of “Hold” by the nine research firms that are presently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average […]
